Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 1 to 10 of 471 total matches.

Ozenoxacin 1% Cream (Xepi) for Impetigo

   
The Medical Letter on Drugs and Therapeutics • Apr 22, 2019  (Issue 1570)
Ozenoxacin 1% Cream (Xepi) for Impetigo ...
The FDA has approved a 1% cream formulation of ozenoxacin (Xepi – Cutanea), a nonfluorinated quinolone antibiotic, for treatment of impetigo caused by Staphylococcus aureus or Streptococcus pyogenes in patients ≥2 months old.
Med Lett Drugs Ther. 2019 Apr 22;61(1570):63-4 | Show Introduction Hide Introduction

Cabotegravir/Rilpivirine (Cabenuva) for HIV-1 Infection

   
The Medical Letter on Drugs and Therapeutics • May 31, 2021  (Issue 1625)
Cabotegravir/Rilpivirine (Cabenuva) for HIV-1 Infection ...
The FDA has approved Cabenuva (ViiV Healthcare), an extended-release formulation of the new integrase strand transfer inhibitor (INSTI) cabotegravir copackaged with an extended-release formulation of the non-nucleoside reverse transcriptase inhibitor (NNRTI) rilpivirine, as a once-monthly complete regimen for intramuscular (IM) treatment of adults with HIV-1 infection who are virologically suppressed (HIV-1 RNA...
Med Lett Drugs Ther. 2021 May 31;63(1625):81-3 | Show Introduction Hide Introduction

Tirbanibulin 1% Ointment (Klisyri) for Actinic Keratosis

   
The Medical Letter on Drugs and Therapeutics • May 03, 2021  (Issue 1623)
Tirbanibulin 1% Ointment (Klisyri) for Actinic Keratosis ...
Tirbanibulin, a microtubule inhibitor, has been approved by the FDA as a 1% ointment (Klisyri – Almirall) for topical treatment of actinic keratosis of the face or scalp.
Med Lett Drugs Ther. 2021 May 3;63(1623):70-1 | Show Introduction Hide Introduction

Cabotegravir (Apretude) for HIV-1 Pre-Exposure Prophylaxis

   
The Medical Letter on Drugs and Therapeutics • Feb 21, 2022  (Issue 1644)
Cabotegravir (Apretude) for HIV-1 Pre-Exposure Prophylaxis ...
The FDA has approved Apretude (ViiV Healthcare), an IM extended-release (ER) formulation of the integrase strand transfer inhibitor (INSTI) cabotegravir, for use every 2 months to prevent sexually acquired HIV-1 infection in at-risk adolescents and adults. Apretude is the first ER formulation to be FDA-approved for pre-exposure prophylaxis (PrEP) of HIV-1 infection.
Med Lett Drugs Ther. 2022 Feb 21;64(1644):29-31 | Show Introduction Hide Introduction

Dolutegravir/Lamivudine (Dovato) - A Two-Drug Complete Regimen for HIV-1 Infection

   
The Medical Letter on Drugs and Therapeutics • Aug 26, 2019  (Issue 1579)
Dolutegravir/Lamivudine (Dovato) - A Two-Drug Complete Regimen for HIV-1 Infection ...
The FDA has approved Dovato (ViiV), a fixed-dose combination of the integrase strand transfer inhibitor (INSTI) dolutegravir (Tivicay) and the nucleoside reverse transcriptase inhibitor (NRTI) lamivudine (Epivir, and generics), as a once-daily complete regimen for treatment of adults with HIV-1 infection who are antiretroviral-treatment naive and have no known substitutions associated with resistance to either drug. Dolutegravir/lamivudine is the first complete regimen to be approved by the FDA for initial treatment of HIV-1 infection that contains 2 rather than 3 antiretroviral...
Med Lett Drugs Ther. 2019 Aug 26;61(1579):134-6 | Show Introduction Hide Introduction

Semaglutide (Ozempic) - Another Injectable GLP-1 Receptor Agonist for Type 2 Diabetes

   
The Medical Letter on Drugs and Therapeutics • Jan 29, 2018  (Issue 1539)
Semaglutide (Ozempic) - Another Injectable GLP-1 Receptor Agonist for Type 2 Diabetes ...
The FDA has approved semaglutide (Ozempic – Novo Nordisk), a long-acting injectable GLP-1 (glucagon-like peptide-1) receptor agonist, for once-weekly treatment of adults with type 2 diabetes. It is the sixth GLP-1 receptor agonist to be approved in the US.
Med Lett Drugs Ther. 2018 Jan 29;60(1539):19-21 | Show Introduction Hide Introduction

Cardiovascular Benefits of SGLT2 Inhibitors and GLP-1 Receptor Agonists in Type 2 Diabetes

   
The Medical Letter on Drugs and Therapeutics • Feb 25, 2019  (Issue 1566)
Cardiovascular Benefits of SGLT2 Inhibitors and GLP-1 Receptor Agonists in Type 2 Diabetes ...
Since 2008, because of safety concerns, the FDA has mandated that long-term cardiovascular outcomes trials be conducted for all new drugs for type 2 diabetes. Reductions in the incidence of macrovascular complications in these trials with some sodium-glucose co-transporter 2 (SGLT2) inhibitors and glucagon-like peptide 1 (GLP-1) receptor agonists in patients at risk for cardiovascular disease (see Table 1) have led to new recommendations.
Med Lett Drugs Ther. 2019 Feb 25;61(1566):26-8 | Show Introduction Hide Introduction

Two New Doses of Dulaglutide (Trulicity) for Diabetes

   
The Medical Letter on Drugs and Therapeutics • Oct 19, 2020  (Issue 1609)
Two New Doses of Dulaglutide (Trulicity) for Diabetes Table 1. Results of AWARD-111 A1C Change ...
The FDA has approved two additional doses (3 mg and 4.5 mg) of the glucagon-like peptide-1 (GLP-1) receptor agonist dulaglutide (Trulicity – Lilly) for treatment of type 2 diabetes in adults. Dulaglutide has been available in 0.75- and 1.5-mg doses for years.
Med Lett Drugs Ther. 2020 Oct 19;62(1609):168 | Show Introduction Hide Introduction

Oral Semaglutide (Rybelsus) for Type 2 Diabetes

   
The Medical Letter on Drugs and Therapeutics • Oct 21, 2019  (Issue 1583)
-1 (GLP-1) receptor agonist semaglutide (Rybelsus – Novo Nordisk) has been approved by the FDA ...
An oral formulation of the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide (Rybelsus – Novo Nordisk) has been approved by the FDA for once-daily treatment of type 2 diabetes in adults. Semaglutide, which has been available in a subcutaneously-injected formulation (Ozempic) since 2017, is the first GLP-1 receptor agonist to become available for oral administration; the 4 other GLP-1 receptor agonists currently available in the US are administered by subcutaneous (SC) injection.
Med Lett Drugs Ther. 2019 Oct 21;61(1583):166-8 | Show Introduction Hide Introduction

Comparison Chart: SGLT2 Inhibitors (online only)

   
The Medical Letter on Drugs and Therapeutics • Nov 16, 2020  (Issue 1611)
2 (SGLT2) INHIBITORS RENAL DOSAGE ADJUSTMENTS CANAGLIFLOZIN eGFR 30 to ...
View the Comparison Chart: SGLT2 Inhibitors
Med Lett Drugs Ther. 2020 Nov 16;62(1611):e184-8 | Show Introduction Hide Introduction